Literature DB >> 20439976

Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Thomas P Monath1.   

Abstract

Two cases of yellow fever vaccine-associated viscerotropic adverse events (YEL-AVD) were identified by review of correspondence received at the Centers for Disease Control and Prevention (CDC; Ft. Collins, CO). The cases occurred in Indiana and Maryland in 1973 and 1978, respectively. One patient, a 75-year-old man with multi-organ failure died, and the other, a 31-year-old woman, was hospitalized for 14 days. Onset was 3-6 days after vaccination. The illness was characterized by fever, headache, myalgia, gastrointestinal symptoms, hepatic and renal dysfunction, and (in the fatal case), shock and coagulopathy, compatible with YEL-AVD. Liver pathology showed diffuse, spotty necrosis, acidophilic degeneration, Kupffer cell hyperplasia, and microvesicular fat. No virological confirmation was obtained, so that both cases remain classified as "suspect." The 1973 case is the earliest record of YEL-AVD; until now, the earliest known case of YEL-AVD had been in 1975 in Brazil, and most subsequent cases have been reported after 1995.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439976      PMCID: PMC2861370          DOI: 10.4269/ajtmh.2010.10-0001

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.

Authors:  Amber R Engel; Pedro F C Vasconcelos; Monica A McArthur; Alan D T Barrett
Journal:  Vaccine       Date:  2006-01-18       Impact factor: 3.641

Review 2.  Acute viscerotropic disease following vaccination against yellow fever.

Authors:  Edward B Hayes
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-07-31       Impact factor: 2.184

3.  Adverse event reports following yellow fever vaccination.

Authors:  Nicole P Lindsey; Betsy A Schroeder; Elaine R Miller; M Miles Braun; Alison F Hinckley; Nina Marano; Barbara A Slade; Elizabeth D Barnett; Gary W Brunette; Katherine Horan; J Erin Staples; Phyllis E Kozarsky; Edward B Hayes
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

4.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

5.  Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.

Authors:  P F Vasconcelos; E J Luna; R Galler; L J Silva; T L Coimbra; V L Barros; T P Monath; S G Rodigues; C Laval; Z G Costa; M F Vilela; C L Santos; P M Papaiordanou; V A Alves; L D Andrade; H K Sato; E S Rosa; G B Froguas; E Lacava; L M Almeida; A C Cruz; I M Rocco; R T Santos; O F Oliva; C M Papaiordanou
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

6.  Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

Authors:  M Martin; T F Tsai; B Cropp; G J Chang; D A Holmes; J Tseng; W Shieh; S R Zaki; I Al-Sanouri; A F Cutrona; G Ray; L H Weld; M S Cetron
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

7.  Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Authors:  Thomas P Monath; Richard Nichols; W Tad Archambault; Linda Moore; Ron Marchesani; Jason Tian; Robert E Shope; Nicola Thomas; Robert Schrader; Dean Furby; Philip Bedford
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

8.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

9.  Viscerotropic disease following yellow fever vaccination in Peru.

Authors:  Alvaro Whittembury; Gladys Ramirez; Herminio Hernández; Alba Maria Ropero; Steve Waterman; María Ticona; Margo Brinton; Jorge Uchuya; Mark Gershman; Washington Toledo; Erin Staples; Clarense Campos; Mario Martínez; Gwong-Jen J Chang; Cesar Cabezas; Robert Lanciotti; Sherif Zaki; Joel M Montgomery; Thomas Monath; Edward Hayes
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more
  7 in total

1.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

2.  Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.

Authors:  Karina Takesaki Miyaji; André Machado Luiz; Amanda Nazareth Lara; Tania do Socorro Souza Chaves; Roberta de Oliveira Piorelli; Marta Heloisa Lopes; Ana Marli Christovam Sartori
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

3.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

Review 4.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

5.  Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.

Authors:  Justin G Julander; Marco Testori; Cédric Cheminay; Ariane Volkmann
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

Review 6.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

7.  Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.

Authors:  Lev Volkov; Gilda Grard; Pierre-Edouard Bollaert; Guillaume A Durand; Aurélie Cravoisy; Marie Conrad; Lionel Nace; Guilhem Courte; Rémy Marnai; Isabelle Leparc-Goffart; Sébastien Gibot
Journal:  BMC Infect Dis       Date:  2020-02-10       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.